Chemotherapy-induced Sclerosing Cholangitis
Overview
Affiliations
Aim: To review the computed tomography (CT), magnetic resonance imaging (MRI) and cholangiographic findings of chemotherapy-induced sclerosing cholangitis (CISC).
Methods: Between January 1995 and December 2004, 11 patients in the endoscopic retrograde cholangiography database were identified with CISC. Twelve CT, four MRI, 69 endoscopic and nine antegrade cholangiographic studies in these patients were reviewed. Serial change in appearance and response to endoscopic treatment were recorded.
Results: CISC showed segmental irregular biliary dilatation with strictures of proximal extrahepatic bile ducts. The distal 5cm of common bile duct was not affected in any patient. CT and MRI findings included altered vascular perfusion of one or more liver segments, liver metastases or peritoneal carcinomatosis. Biliary strictures needed repeated stenting in 10 patients (mean: every 4.7 months). Cirrhosis (n=1) or confluent fibrosis (n=0) were uncommon findings.
Conclusion: CISC shares similar cholangiographic appearances to primary sclerosing cholangitis (PSC). Unlike PSC, biliary disease primarily involved ducts at the hepatic porta rather than intrahepatic ducts. Multiphasic contrast-enhanced CT or MRI may show evidence of perfusion abnormalities, cavitary liver lesions, or metastatic disease.
Zhao J, Yue P, Mi N, Li M, Fu W, Zhang X Med Rev (2021). 2024; 4(4):326-365.
PMID: 39135601 PMC: 11317084. DOI: 10.1515/mr-2024-0029.
Moller K, Braden B, Culver E, Jenssen C, Safai Zadeh E, Alhyari A Endosc Ultrasound. 2023; 12(2):181-199.
PMID: 36588352 PMC: 10237613. DOI: 10.4103/EUS-D-22-00208.
Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.
Tanaka T, Sakai A, Tsujimae M, Yamada Y, Kobayashi T, Masuda A World J Gastroenterol. 2022; 28(28):3732-3738.
PMID: 36161046 PMC: 9372812. DOI: 10.3748/wjg.v28.i28.3732.
Barman M, Al Hariri B, Rahman Mustafa A, Ambra N, Amjed I, Alharafsheh A Qatar Med J. 2022; 2022(3):27.
PMID: 35864919 PMC: 9272765. DOI: 10.5339/qmj.2022.27.
Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis.
Calistri L, Rastrelli V, Nardi C, Maraghelli D, Vidali S, Pietragalla M World J Gastroenterol. 2022; 27(46):7866-7893.
PMID: 35046618 PMC: 8678821. DOI: 10.3748/wjg.v27.i46.7866.